Kymera Therapeutics (KYMR) investor relations material

Company strategy and market opportunity

• Focus on targeted protein degradation to address previously undruggable targets, with a primary emphasis on immunology and oral therapies for Type 2 diseases.

• Target patient population for initial drugs is estimated at 40–50 million, with current advanced systemic therapy penetration at only 1–2 million.

• Market for Type 2 disease drugs is $20–25 billion annually, with potential for 5–10x expansion as oral drugs with biologics-like efficacy enter the space.

• Oral drugs are highly desired by patients and prescribers due to convenience and psychological barriers to injections, with significant unmet need in pediatric populations.

• The company aims to deliver biologics-level efficacy in an oral format, which could transform treatment paradigms and market size.

Clinical development and data insights

• KT-621 has shown a clean safety profile in early studies, with no treatment-related adverse events reported; more detailed data will be published soon.

• Phase Ib data demonstrated deep target degradation, robust biomarker changes, and clinical improvements in AD patients, with efficacy in the dupilumab range at day 28.

• All measured endpoints and biomarkers moved in the same positive direction, with some results numerically superior to existing biologics.

• The company expects efficacy to improve beyond the four-week mark, based on the trajectory of clinical response curves.

• The main goal of the ongoing phase II study is dose selection for phase III, with careful attention to baseline characteristics and placebo effects.

Competitive landscape and future outlook

• No direct analog exists for an oral drug with biologics-like efficacy entering this market, making the program potentially transformative.

• Historical success of less efficacious oral drugs (e.g., Otezla) highlights the potential for even greater success with a more effective oral therapy.

• The company is confident in the asthma indication based on FeNO biomarker reductions and preclinical data.

• For pipeline programs like IRF5, strong genetic validation and targeted biological effects in specific immune cells provide confidence for clinical translation.

• The company anticipates significant value creation as programs advance, with a focus on robust data and careful trial design.